Georgia Nephrology Research Institute
Welcome,         Profile    Billing    Logout  
 5 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tumlin, James A
MRA-ACE, NCT03502031: Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Recruiting
4
72
US
Renin-Angiotensin (RAAS) alone, Lispril, Enalapril, Perindopril, Losarta, Valsar etc.,, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone, Lisinopril, Enalapril, Perindopril, Losartan, Valsartan, or Spironolactone
James A. Tumlin, MD, Nelson Kopyt, MD
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
10/22
10/24
ADAPT, NCT05535920: A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Completed
4
88
US
LOKELMA 5 GM Powder for Oral Suspension
NephroNet, Inc., AstraZeneca
Hyperkalemia
04/24
04/24
FACT, NCT05546047: A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Active, not recruiting
4
34
US
Acthar Gel 80 UNT/ML Injectable Solution, Tacrolimus 1.0 mg
NephroNet, Inc., Mallinckrodt
Fibrillary Glomerulonephritis
10/23
10/24
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
NCT03955445 / 2018-004253-24: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
3
225
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
05/36
05/36
HUMAXX, NCT05908084: To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Recruiting
3
150
US
Acellular Tissue Engineered Vessel (ATEV), Human Acellular Vessel (HAV), AVF
Humacyte, Inc., IQVIA Biotech
End Stage Renal Disease (ESRD)
10/26
10/27
APPEAR-C3G, NCT04817618 / 2020-004589-21: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Hourglass Jul 2024 - Dec 2024 : Submission for the adult C3G
Hourglass Jul 2024 - Dec 2024 : Submission in US for the adult C3G
Recruiting
3
98
Europe, Canada, Japan, US, RoW
Placebo, iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
C3G
03/26
07/26
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

Active, not recruiting
2
60
US
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Mineralys Therapeutics Inc.
Chronic Kidney Disease
05/25
05/25
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
NCT06824987: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Recruiting
2
96
Europe, US
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
AstraZeneca
APOL1-Mediated Kidney Disease
08/27
08/27
NCT06064929: A Study of Felzartamab in Participants With Lupus Nephritis

Recruiting
1/2
20
Canada, US, RoW
Felzartamab, HIB202
HI-Bio, A Biogen Company
Lupus Nephritis
06/26
06/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
Jodice, Erika
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT03955445 / 2018-004253-24: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
3
225
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
05/36
05/36
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
Research, Georgia N
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tumlin, James A
MRA-ACE, NCT03502031: Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Recruiting
4
72
US
Renin-Angiotensin (RAAS) alone, Lispril, Enalapril, Perindopril, Losarta, Valsar etc.,, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone, Lisinopril, Enalapril, Perindopril, Losartan, Valsartan, or Spironolactone
James A. Tumlin, MD, Nelson Kopyt, MD
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
10/22
10/24
ADAPT, NCT05535920: A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Completed
4
88
US
LOKELMA 5 GM Powder for Oral Suspension
NephroNet, Inc., AstraZeneca
Hyperkalemia
04/24
04/24
FACT, NCT05546047: A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Active, not recruiting
4
34
US
Acthar Gel 80 UNT/ML Injectable Solution, Tacrolimus 1.0 mg
NephroNet, Inc., Mallinckrodt
Fibrillary Glomerulonephritis
10/23
10/24
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
NCT03955445 / 2018-004253-24: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
3
225
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
05/36
05/36
HUMAXX, NCT05908084: To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Recruiting
3
150
US
Acellular Tissue Engineered Vessel (ATEV), Human Acellular Vessel (HAV), AVF
Humacyte, Inc., IQVIA Biotech
End Stage Renal Disease (ESRD)
10/26
10/27
APPEAR-C3G, NCT04817618 / 2020-004589-21: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Hourglass Jul 2024 - Dec 2024 : Submission for the adult C3G
Hourglass Jul 2024 - Dec 2024 : Submission in US for the adult C3G
Recruiting
3
98
Europe, Canada, Japan, US, RoW
Placebo, iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
C3G
03/26
07/26
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

Active, not recruiting
2
60
US
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Mineralys Therapeutics Inc.
Chronic Kidney Disease
05/25
05/25
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
NCT06824987: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Recruiting
2
96
Europe, US
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
AstraZeneca
APOL1-Mediated Kidney Disease
08/27
08/27
NCT06064929: A Study of Felzartamab in Participants With Lupus Nephritis

Recruiting
1/2
20
Canada, US, RoW
Felzartamab, HIB202
HI-Bio, A Biogen Company
Lupus Nephritis
06/26
06/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
Jodice, Erika
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT03955445 / 2018-004253-24: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
3
225
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
05/36
05/36
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
Research, Georgia N
No trials found

Download Options